Our Bifunctional Antibody

PLT011 is a human bifunctional anti-PD-L1/IL-10 fusion protein, composed of an anti-PD-L1 antibody linked to IL-10 polypeptides. By leveraging the targeting capability of the anti-PD-L1 antibody, PLT011 localizes specifically to the tumor microenvironment, effectively boosting and reinvigorating CD8+ T cells without inducing systemic immune activation. The IL-10-mediated rejuvenation of CD8+ T cells is further enhanced by PLT011’s anti-PD-L1 activity, amplifying anti-tumor immunity. Notably, Pilatus has demonstrated that PLT011 delivers remarkable anti-tumor efficacy in HCC and melanoma mouse models, reprogramming CD8+ T cell exhaustion while maintaining limited toxicity. These findings underscore the potential of PLT011 to address key challenges in immunotherapy and advance the field.